We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Feraccru

News List

Feraccru granted major extension to approval in Switzerland firstwordpharma
April 25, 2019
London, UK, 24th April 2019: Shield Therapeutics plc (LSE:STX), a commercial stage, pharmaceutical company with a focus on addressing iron deficiency with or without anaemia via its lead product Feraccru® ...
Shield expecting US decision on Feraccru in July pharmatimes
December 14, 2018
Shield Therapeutics has revealed that the US Food and Drug Administration will make a decision on its application to market Feraccru in the US by July 27 next year.
Norgine launches Shield’s Feraccru in the UK pharmatimes
December 07, 2018
Norgine has launched Feraccru across the UK to treat patients with iron deficiency anaemia, having picked up rights to sell the drug from Shield Therapeutics earlier this year.
Shield’s Feraccru accepted for review in the US pharmatimes
December 06, 2018
Shield Therapeutics’ iron deficiency drug Feraccru has been accepted for review by the US Food and Drug Administration (FDA).